Literature DB >> 28942642

Experimental Evolution of Diverse Strains as a Method for the Determination of Biochemical Mechanisms of Action for Novel Pyrrolizidinone Antibiotics.

Kathryn Beabout1, Megan D McCurry1, Heer Mehta1, Akshay A Shah2, Kiran Kumar Pulukuri2, Stephan Rigol2, Yanping Wang2, K C Nicolaou2, Yousif Shamoo1.   

Abstract

The continuing rise of multidrug resistant pathogens has made it clear that in the absence of new antibiotics we are moving toward a "postantibiotic" world, in which even routine infections will become increasingly untreatable. There is a clear need for the development of new antibiotics with truly novel mechanisms of action to combat multidrug resistant pathogens. Experimental evolution to resistance can be a useful tactic for the characterization of the biochemical mechanism of action for antibiotics of interest. Herein, we demonstrate that the use of a diverse panel of strains with well-annotated reference genomes improves the success of using experimental evolution to characterize the mechanism of action of a novel pyrrolizidinone antibiotic analog. Importantly, we used experimental evolution under conditions that favor strongly polymorphic populations to adapt a panel of three substantially different Gram-positive species (lab strain Bacillus subtilis and clinical strains methicillin-resistant Staphylococcus aureus MRSA131 and Enterococcus faecalis S613) to produce a sufficiently diverse set of evolutionary outcomes. Comparative whole genome sequencing (WGS) between the susceptible starting strain and the resistant strains was then used to identify the genetic changes within each species in response to the pyrrolizidinone. Taken together, the adaptive response across a range of organisms allowed us to develop a readily testable hypothesis for the mechanism of action of the CJ-16 264 analog. In conjunction with mitochondrial inhibition studies, we were able to elucidate that this novel pyrrolizidinone antibiotic is an electron transport chain (ETC) inhibitor. By studying evolution to resistance in a panel of different species of bacteria, we have developed an enhanced method for the characterization of new lead compounds for the discovery of new mechanisms of action.

Entities:  

Keywords:  antibiotic resistance; antibiotics; experimental evolution; mechanism of action; pyrrolizidinone

Mesh:

Substances:

Year:  2017        PMID: 28942642      PMCID: PMC5817888          DOI: 10.1021/acsinfecdis.7b00135

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  58 in total

1.  Proteomic approach to understanding antibiotic action.

Authors:  Julia Elisabeth Bandow; Heike Brötz; Lars Ingo Ole Leichert; Harald Labischinski; Michael Hecker
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

2.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Temperature-sensitive mutations at the carboxy terminus of the alpha subunit of the Escherichia coli F1F0 ATP synthase.

Authors:  S B Vik; D Lee; P A Marshall
Journal:  J Bacteriol       Date:  1991-07       Impact factor: 3.490

Review 4.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Overcoming the current deadlock in antibiotic research.

Authors:  Till F Schäberle; Ingrid M Hack
Journal:  Trends Microbiol       Date:  2014-04       Impact factor: 17.079

6.  Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium.

Authors:  Vincent Cattoir; Christophe Isnard; Thibaud Cosquer; Arlène Odhiambo; Fiona Bucquet; François Guérin; Jean-Christophe Giard
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

7.  Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance.

Authors:  Corwin Miller; Jiayi Kong; Truc T Tran; Cesar A Arias; Gerda Saxer; Yousif Shamoo
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

8.  A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

Authors:  Fionnuala McAleese; Peter Petersen; Alexey Ruzin; Paul M Dunman; Ellen Murphy; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

9.  Membrane lipid changes during formation of a functional electron transport system in Staphylococcus aureus.

Authors:  F E Frerman; D C White
Journal:  J Bacteriol       Date:  1967-12       Impact factor: 3.490

10.  Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance.

Authors:  Laura Villa; Claudia Feudi; Daniela Fortini; Aurora García-Fernández; Alessandra Carattoli
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

View more
  3 in total

1.  Enantioselective Total Synthesis of Antibiotic CJ-16,264, Synthesis and Biological Evaluation of Designed Analogues, and Discovery of Highly Potent and Simpler Antibacterial Agents.

Authors:  K C Nicolaou; Kiran Kumar Pulukuri; Stephan Rigol; Marek Buchman; Akshay A Shah; Nicholas Cen; Megan D McCurry; Kathryn Beabout; Yousif Shamoo
Journal:  J Am Chem Soc       Date:  2017-10-24       Impact factor: 15.419

2.  Novel Immune Modulators Enhance Caenorhabditis elegans Resistance to Multiple Pathogens.

Authors:  Nicholas A Hummell; Alexey V Revtovich; Natalia V Kirienko
Journal:  mSphere       Date:  2021-01-06       Impact factor: 4.389

3.  Microfluidic platform for spatially segregated experimental evolution studies with E. coli.

Authors:  Seokju Seo; Ramya Ganiga Prabhakar; Saoirse Disney-McKeethen; Xinhao Song; Yousif Shamoo
Journal:  STAR Protoc       Date:  2022-04-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.